StockData
Rani Therapeutics Holdings, Inc. logo

Rani Therapeutics Holdings, Inc. (RANI) stock

RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3043% above fair value
$0.65+0.09 (+15.86%)

Close on Nov 18, 2026Market cap $90.34MP/E –Yield –

Rani Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Rani Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -618.0%. For fiscal 2025 it was -1817.1%, against -2920.0% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-1817.1%+1103.0
FY2024Dec 31, 2024-2920.0%−2613.4
FY2021Dec 31, 2021-306.6%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-432.7%+437.6
Q1 FY2026Mar 31, 2026-411.8%−132.1
Q4 FY2025Dec 31, 2025-705.3%+35.1
Q1 FY2025Mar 31, 2025-4223.3%−1553.8
Q4 FY2024Dec 31, 2024-870.3%+3653.0
Q2 FY2021Jun 30, 2021-279.7%–
Q1 FY2021Mar 31, 2021-740.5%–
Q3 FY2020Sep 30, 2020-2669.4%–
Q2 FY2020Jun 30, 2020-4523.3%–

More Rani Therapeutics figures

See a number that looks wrong?